Key clinical point: Decreased levels of plasma apolipoprotein M (APOM) were associated with worsened mortality outcomes in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor-2 negative (HER2−) metastatic breast cancer (BC).
Major finding: Mean baseline plasma APOM levels were significantly lower in patients who had deceased vs survived during the 24-month follow-up period (42.7 vs 52.2 µg/mL; P = .003), and the doubling of plasma APOM levels was associated with an improvement in the overall survival outcomes (adjusted hazard ratio 0.23; P = .001).
Study details: This study measured APOM plasma levels in 75 patients with ER+/HER2− metastatic BC.
Disclosures: This study was partly sponsored by the European Regional Development fund. The authors declared no conflicts of interest.
Source: Muendlein A et al. Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients. Breast Cancer Res Treat. 2023 (Jul 25). doi: 10.1007/s10549-023-07045-4